AstraZeneca expands StarPharma deal for cancer drug delivery tech

DEP delivery tech--Courtesy of StarPharma

AstraZeneca ($AZN) has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline, according to a release. StarPharma's DEP delivery tech, which uses dendrimers to carry drugs to a targeted receptor, has been used to deliver the cancer drug docetaxel most often in the past, but the companies said back at the outset of their agreement that they would not be focusing their efforts there. Under the deal, AstraZeneca is set to provide funding for preclinical research conducted jointly. Release